论文部分内容阅读
目的 观察盐酸多奈哌齐治疗卒中后认知障碍非痴呆(PSCIND)的疗效.方法 近年就诊的急性脑梗死患者经MoCA量表筛选PSCIND患者110 例.随机分为2组,给予盐酸多奈哌齐口服的患者入试验组(n＝67),未使用者为对照组(n＝43).治疗前、治疗后6 个月进行NIHSS、MoCA、mRS评分.比较疗效.结果 2组患者年龄、性别、血压、治疗前NIHSS、MoCA等差异均无统计学意义(P＞0.05).治疗6 个月后,试验组MoCA高于对照组[(24.13±1.92) vs (22.16±1.76),P＝0.000];亦较治疗前增高[(24.13±1.92) vs (22.67±1.40),P＝0.000];对照组较治疗前降低[(22.16±1.76) vs (23.09±1.44),P＝0.000].6 个月后mRS评分试验组低于对照组[(1.99±1.35) vs (2.74±1.77),P＝0.013].结论 卒中后早期应用盐酸多奈哌齐治疗可有效改善PSCIND患者认知功能和综合生活能力.“,”Objective To observe the efficacy of donepezil hydrochloride in the treatment of post-stroke cognitive impairment no dementia (PSCIND). Methods 110 patients with PSCIND were screened by MoCA scale in recent years. They were randomly divided into two groups. The patients who were given donepezil hydrochloride orally were enrolled in the experimental group (n＝67), while the non-users were in the control group (n＝43). NIHSS, MoCA and mRS were scored before and 6 months after treatment. The curative effect were compared. Results There were no significant differences in age, sex, blood pressure, NIHSS and MoCA before treatment between the two groups (P＞0.05). After 6 months of treatment, MoCA in the experimental group was higher than that in the control group [(24.13±1.92) vs (22.16±1.76), P＝0.000]. The experimental group was also higher than that before treatment [(24.13±1.92) vs (22.67±1.40), P＝0.000], while the control group was lower than that before treatment [(22.16±1.76) vs (23.09±1.44), P＝0.000]. After 6 months, the mRS score of the experimental group was lower than that of the control group [(1.99±1.35) vs (2.74±1.77), P＝0.013]. Conclusion Donepezil hydrochloride can effectively improve the cognitive function and comprehensive living ability of patients with PSCIND in the early stage after stroke.